The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...

Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...

In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...

Amgen didn't clarify whether the average weight reduction of up to about 20% was a placebo-adjusted figure. It most likely referred to total weight loss, which means the candidate probably isn't any ...

Also Read: 99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly’s Detailed Phase 3 Data Shows ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 billion ...

The Biden administration is proposing a major expansion of how Medicare and Medicaid cover the weight-loss drugs Wegovy and ...

Delving into the details, we found 12% of traders were bullish, while 75% showed bearish tendencies. Out of all the trades we ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...